The festival’s opening-night gala will feature the West Coast Premiere of Tom Nesher’s Come Closer at the Saban Theatre in Beverly Hills.

People affected by rare blood clots say they feel they have been airbrushed out of the pandemic.

The easily spreadable virus can affect people of all ages and have huge consequences during winter.

Steven A. Carr
Mar 1, 2014; 13:907-917
Technological Innovation and Resources

Now is the moment to launch an African vaccine industry The World Today mhiggins.drupal 31 July 2022

The continent plans to make 60 per cent of its vaccines by 2040. After the failure of the world to help in the pandemic, it’s high time, says Ngozi Erondu.

The lack of an African vaccine industry has been a glaring concern for decades. Before the pandemic, 99 per cent of Africa’s vaccines were manufactured outside the continent. As well as endangering the lives of millions, this situation has inhibited social and economic progress on the continent.

In response, the Africa Centres for Disease Control and Prevention (Africa CDC) has undertaken an ambitious plan, outlined in the Partnerships for African Vaccine Manufacturing (PAVM) Framework for Action, to develop the nascent African vaccine manufacturing sector into an end-to-end industry by 2040. The framework aims to raise the share of African-manufactured vaccines used across the continent to 60 per cent by 2040, or the equivalent to up to 1.7 billion doses annually.

Seven of every 10 vaccines used in Africa are currently donated through Gavi, the Vaccine Alliance. Most are administered within childhood immunization programmes and are largely manufactured either in India, or by  multinational vaccine manufacturers in North America or Japan.

Vaccine donations have inhibited the development in Africa of vaccines and other countermeasures against diseases.

Though the Ebola virus was discovered in Central Africa in 1976, vaccine development was not adequately funded until it emerged in Europe in 2014. Human monkeypox resurfaced in Nigeria in 2017, yet the global Coalition for Epidemic Preparedness Innovations only targeted it for vaccine development in July this year.

The pandemic highlighted Africa’s fatal dependency on imported vaccines. Only 20 per cent of Africans are fully vaccinated against Covid-19, due to the failure of countries in the Global North to ensure the equitable distribution of vaccines via the COVAX facility to 40 per cent of the world’s most vulnerable people. 

The pandemic also confirmed that Africa could not rely on fellow states of the Global South. At the height of the Delta variant outbreak in early 2021, India halted vaccine exports to Africa, where only 1.5 per cent of the population had at that time received any vaccine doses.

After decades of discussions, there are signs that Africa could soon succeed in creating its own vaccine industry. First, the 55-member African Union is in the process of establishing the African Medicines Agency, a regional regulatory body. 
 

‘The new public health order’

Additionally, the African Export-Import Bank and African Development Bank (AfDB) have established a foundation to provide financial and strategic support for the development of the pharmaceutical industry and the consolidation of regional vaccination programmes in Africa (the foundation would potentially negotiate intellectual property rights and licensing issues but that remains to be seen).

Second, studies show there is an emerging middle class in Africa. In a 2011 report by the AfDB, this was estimated at some 56 million households. Potentially, this means many people will be able to buy vaccines and medicines made in Africa.

About a third of African countries currently pay for their vaccine needs. According to PAVM forecasts, the value of the total African market could reach between $3 billion and $17 billion by 2040.

The recent entry into effect of the African Continental Free Trade Area should also prove conducive to African vaccine development. Through economic integration, free movement and harmonized regional standards, countries that invest in their biopharmaceutical and medical technology sectors may attract employees, regional and international businesses, and investment. Further, the pandemic has encouraged people to relocate to countries with, or planning for, universal healthcare.

Building an African pharmaceutical industry from the ground up could take much longer than two decades and cost tens of billions of dollars. Nevertheless, the moment seems ripe, and timely support has been forthcoming from influential regional actors, including Rwandan President Paul Kagame, South Africa’s Cyril Ramaphosa, and private sector business executives, including the Zimbabwean-born billionaire Strive Masiyiwa.

With a pandemic treaty embedding equity in prevention, preparedness and response some way off, and given the limitations surrounding the recent World Trade Organization compromise on the TRIPS waiver – which temporarily waives Covid-19 vaccine patent protections for poorer countries – it is doubly important for Africa to build up its own pharmaceutical industry and emergency systems. 

In 2021, John Nkengasong, then director of Africa CDC, wrote of the necessity of a post-pandemic ‘new public health order’ for Africa. Such a change may threaten the global health organizations, industries and institutes who derive payment from ‘saving Africa’ during emergencies. Additionally, through strengthening Africa CDC, other actors such as the World Health Organization may find that they have a diminished strategic role on the continent.
 
While Africa should not dismiss these valuable and long-standing partnerships, it must take the opportunity to advance its interests and to assume leadership in this important area.

Annika Nelde
Dec 7, 2020; 0:R120.002309v1-mcp.R120.002309
Review

Frank C. Nichols
Dec 1, 2020; 61:1645-1657
Research Articles

Porphyromonas gingivalis is a Gram-negative anaerobic periodontal microorganism strongly associated with tissue-destructive processes in human periodontitis. Following oral infection with P. gingivalis, the periodontal bone loss in mice is reported to require the engagement of Toll-like receptor 2 (TLR2). Serine-glycine lipodipeptide or glycine aminolipid classes of P. gingivalis engage human and mouse TLR2, but a novel lipid class reported here is considerably more potent in engaging TLR2 and the heterodimer receptor TLR2/TLR6. The novel lipid class, termed Lipid 1256, consists of a diacylated phosphoglycerol moiety linked to a serine-glycine lipodipeptide previously termed Lipid 654. Lipid 1256 is approximately 50-fold more potent in engaging TLR2 than the previously reported serine-glycine lipid classes. Lipid 1256 also stimulates cytokine secretory responses from peripheral blood monocytes and is recovered in selected oral and intestinal Bacteroidetes organisms. Therefore, these findings suggest that Lipid 1256 may be a microbial TLR2 ligand relevant to chronic periodontitis in humans.

The approach of peptide-based anti-cancer vaccination has proven the ability to induce cancer-specific immune responses in multiple studies for various cancer entities. However, clinical responses remain so far limited to single patients and broad clinical applicability was not achieved. Therefore, further efforts are required to improve peptide vaccination in order to integrate this low side effect therapy into the clinical routine of cancer therapy. To design clinically effective peptide vaccines in the future, different issues have to be addressed and optimized comprising antigen target selection as well as choice of optimal adjuvants and vaccination schedules. Furthermore, the combination of peptide-based vaccines with other immuno- and molecular targeted therapies as well as the development of predictive biomarkers could further improve efficacy. In this review, current approaches in the development of peptide-based vaccines and critical implications for optimal vaccine design are discussed.

HANOVER, Md., Nov. 5, 2024 — Ciena has announced that its optical and routing and switching innovations will once again support the SCinet network at SC24, taking place November 17–22 […]

The post Ciena Powers SC24’s SCinet with High-Speed Connectivity and Advanced Optical Solutions appeared first on HPCwire.

A new study indicates what researchers describe as an ongoing "stubborn mistrust" in science among the American public as it relates to COVID-19 vaccines.

Two infectious disease experts weigh in on how a COVID-19 vaccine that’s 90 percent effective, as early results are showing, could change school health and safety protocols.

“Vaccines are a choice and people have the choice and will have the choice in this state as to whether or not they should take that vaccine,” the governor said.

“Vaccines are a choice and people have the choice and will have the choice in this state as to whether or not they should take that vaccine,” the governor said.

The GluN3A subunit of N-methyl-D-aspartate receptors (NMDARs) plays an established role in synapse development, but its contribution to neural circuits in the adult brain is less clear. Recent work has demonstrated that in select cell populations, GluN3A assembles with GluN1 to form GluN1/GluN3A receptors that are insensitive to glutamate and instead serve as functional excitatory glycine receptors (eGlyRs). Our understanding of these eGlyRs, and how they contribute to intrinsic excitability and synaptic communication within relevant networks of the developing and the mature brain, is only beginning to be uncovered. Here, using male and female mice, we demonstrate that GluN3A subunits are enriched in the adult ventral hippocampus (VH), where they localize to synaptic and extrasynaptic sites and can assemble as functional eGlyRs on CA1 pyramidal cells. GluN3A expression was barely detectable in the adult dorsal hippocampus (DH). We also observed a high GluN2B content in the adult VH, characterized by slow NMDAR current decay kinetics and a high sensitivity to the GluN2B-containing NMDAR antagonist ifenprodil. Interestingly, the GluN2B enrichment in the adult VH was dependent on GluN3A as GluN3A deletion accelerated NMDAR decay and reduced ifenprodil sensitivity in the VH, suggesting that GluN3A expression can regulate the balance of conventional NMDAR subunit composition at synaptic sites. Lastly, we found that GluN3A knock-out also enhanced both NMDAR-dependent calcium influx and NMDAR-dependent long-term potentiation in the VH. Together, these data reveal a novel role for GluN3A and eGlyRs in the control of ventral hippocampal circuits in the mature brain.

The Food and Agriculture Organization of the United Nations (FAO) is organizing its first-ever Global Conference on Animal Health Innovation, Reference Centres and Vaccines from 23 to 25 September at FAO headquarters [...]

Have you ever wondered how a simple shot can keep you from dying a horrible death? In this one-minute video, Ask Smithsonian’s host, Eric Schulze, unravels how vaccines boot-camp our bodies into shape, getting us ready to fight off deadly diseases.

Victor Ambros and Gary Ruvkun discovered microRNA, tiny molecules that play a crucial role in how cells develop, paving the way for new treatments for diseases

Colossal Biosciences reports it extracted DNA and RNA from the Tasmanian tiger specimen, a key step forward in its effort to create a modern proxy of the extinct species. Other scientists are calling for data to back up the claim

In the 1960s, a vaccine for chlamydia made patients more susceptible to chlamydia. Now scientists know why

Health officials say it’s the right time to get your seasonal flu and COVID-19 vaccines as levels of both viruses rise in Ottawa. The CBC’s Kimberley Molina reports.

The OM team in Bar, Montenegro, received an enthusiastic response when they showed the JESUS film in the Roma language for the first time.

The question has increasing urgency as coronavirus rates surge and more public health experts say keeping schools open is essential.

First and second-year medical students at the Penn State College of Medicine participated in a simulated rope rescue of an injured climber.

Temporary codification of expanded telemedicine options helps all Delawareans Today Governor John Carney signed, via livestream, HS 1 for HB 348, sponsored by Representative David Bentz, which temporarily codifies a number of consumer-friendly provisions developed during COVID-19 that can increase access to health care due to expanding telemedicine. Insurance Commissioner Trinidad Navarro issued the following […]

Local independent pharmacy to administer important immunizations Insurance Commissioner Trinidad Navarro, in collaboration with Lieutenant Governor Bethany Hall-Long and Kevin Musto, R.Ph., FAPhA, independent pharmacist with Atlantic Apothecary, has announced a COVID Vaccination and Flu Shot Clinic on Thursday, November 18 from 1:00 to 4:00PM at the Delaware Department of Insurance’s Dover Office, 1351 West […]

WILMINGTON, DE – The Delaware Department of Labor (DOL) has issued policy to address questions and concerns about a claimant’s eligibility to collect Unemployment Insurance (UI) benefits after refusing to be vaccinated or tested as required by an employer. Delaware law states that claimants are not allowed to receive UI benefits if they have violated […]

DOVER, DE (Dec. 21, 2021) – The Delaware Division of Public Health (DPH) announced today that individuals vaccinated in Delaware will now have access to a QR code when downloading their COVID-19 vaccination record. The digital COVID-19 vaccination card now includes the QR code and is available through the DelVAX Public Portal, a site where those who were […]

The Delaware Division of Public Health (DPH) today announced that Delaware’s vaccine providers can now begin administering booster doses of the Pfizer-BioNTech COVID-19 vaccine to individuals ages 12 to 15 who completed their initial Pfizer vaccine series at least five months ago.

DOVER, DE (February 11, 2022) – The Delaware Division of Public Health (DPH) is providing an update on the most recent statistics related to coronavirus disease 2019 (COVID-19) in Delaware, as of Thursday, Feb 10, 2022. Over the past month, the state has seen a significant decrease in the average percentage of tests that are positive, […]

DOVER, DE (June 17, 2022) – The Delaware Division of Public Health (DPH) reports an overall decrease in COVID-19 cases and hospitalization since the previous monthly COVID-19 update released on May 21, 2022. While COVID-19 cases, hospitalizations, and deaths are experiencing a decreasing trend, DPH encourages Delawareans to rely on trusted prevention actions to stay one step ahead of COVID-19 during this event-filled weekend that […]

DOVER, DE (June 18, 2022) – Parents of children ages 6 months through 5 years old, will be able to get their children vaccinated against COVID-19 starting the week of June 20, 2022, according to the Division of Public Health (DPH). Vaccines for this youngest age group received final sign off for Emergency Use Authorization, from the Food […]

The Delaware Division of Public Health (DPH) is announcing five additional cases of monkeypox (MPX), bringing the state’s total to 11. All cases are considered probable pending confirmatory testing by the Centers for Disease Control and Prevention (CDC).

The Delaware Division of Public Health (DPH) is announcing additional locations where those who meet eligibility criteria can get the monkeypox (MPX) vaccine. On Monday, DPH expanded access to the vaccine to those living with HIV and those receiving HIV pre-exposure prophylaxis (PrEP).

The Delaware Division of Public Health (DPH) is announcing six additional cases of monkeypox (MPX), bringing the state’s total to 17. 

DOVER, DE (Sept 22, 2022) ­– The Delaware Division of Public Health (DPH) is sharing upcoming opportunities for individuals to get vaccinated against the monkeypox virus (MPX). The current case count for MPX in the state is 35, including 23 cases in New Castle County, three cases in Kent County, and nine cases in Sussex County. Delaware continues […]

Per the CDC, vaccination remains the best protection against COVID-19-related hospitalization and death and reduces the chance of suffering from Long COVID.  Anyone who has yet to receive any type of COVID-19 vaccination and those whose last dose of any COVID-19 vaccine was over two months ago may receive the updated doses when they become available in the coming days.

DEPARTMENT OF HEALTH AND SOCIAL SERVICES: Division of Medicaid and Medical Assistance

Sustainability is gaining traction in the creative industries, with the Italian region of Trentino designing a film production rating protocol that is being considered by the EU.

vaccines work flow chart completed

Colossal, a US firm that is aiming to revive lost species such as the woolly mammoth, says it now has a near-complete genome of the extinct thylacine